Arena Pharmaceuticals Inc

+0.32 (+0.49%)
Regulatory, Other Pre-Announcement

Arena Reports Advancing Etrasimod Into A Phase 3 Program In Atopic Dermatitis

Published: 11/09/2020 22:42 GMT
Arena Pharmaceuticals Inc (ARNA) - Arena Reports Third Quarter Financial Results With Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis.
Q3 Loss per Share $1.69.
Q3 Earnings per Share Estimate $-1.87 -- Refinitiv Ibes Data (analyst estimates).
Arena Pharma - Completed Enrollment of Captivate Ph 2b Trial Evaluating Olorinab in Irritable Bowel Syndrome Pain, Topline Data Expected Q1 2020.
Cash, Cash Equivalents and Marketable Securities of $1.2 Billion As of September 30, 2020.
Basic and Diluted Net Loss per Share for Q3 Was $1.69.
Q3 Earnings per Share View $-1.87 -- Refinitiv Ibes Data (analyst estimates).